A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

被引：0
|
作者：
Laura Q. M. Chow
S. Gail Eckhardt
Cindy L. O’Bryant
Mary Kay Schultz
Mark Morrow
Stacy Grolnic
Michele Basche
Lia Gore
机构：
[1] University of Colorado Cancer Center,
[2] The Children’s Hospital,undefined
[3] University of Colorado Health Sciences Center at Fitzsimons,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2008年 / 62卷
关键词：
Lonafarnib; SCH66336; Cisplatin; Gemcitabine; Farnesyltransferase; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：631 / 646
页数：15
相关论文
共 50 条
  • [21] Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor
    Sparreboom, A
    Kehrer, DFS
    Mathijssen, RHJ
    Xie, R
    de Jonge, MJA
    de Bruijn, P
    Planting, T
    Eskens, FALM
    Verheij, C
    de Heus, G
    Klaren, A
    Zhang, S
    Verhaeghe, T
    Palmer, PA
    Verweij, J
    BRITISH JOURNAL OF CANCER, 2004, 90 (08) : 1508 - 1515
  • [22] Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors
    Castaneda, Carlos
    Meadows, Kellen L.
    Truax, Roxanne
    Morse, Michael A.
    Kaufmann, Scott H.
    Petros, William P.
    Zhu, Yali
    Statkevich, Paul
    Cutler, David L.
    Hurwitz, Herbert I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (02) : 455 - 463
  • [23] Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors
    Carlos Castaneda
    Kellen L. Meadows
    Roxanne Truax
    Michael A. Morse
    Scott H. Kaufmann
    William P. Petros
    Yali Zhu
    Paul Statkevich
    David L. Cutler
    Herbert I. Hurwitz
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 455 - 463
  • [24] A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors
    Gietema, J. A.
    Hoekstra, R.
    de Vos, F. Y. F. L.
    Uges, D. R. A.
    van der Gaast, A.
    Groen, H. J. M.
    Loos, W. J.
    Knight, R. A.
    Carr, R. A.
    Humerickhouse, R. A.
    Eskens, F. A. L. M.
    ANNALS OF ONCOLOGY, 2006, 17 (08) : 1320 - 1327
  • [25] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Metaxas, Yannis
    Kahatt, Carmen
    Alfaro, Vicente
    Fudio, Salvador
    Zeaiter, Ali
    Plummer, Ruth
    Sessa, Cristiana
    Von Moos, Roger
    Forster, Martin
    Stathis, Anastasios
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 91 - 98
  • [26] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Yannis Metaxas
    Carmen Kahatt
    Vicente Alfaro
    Salvador Fudio
    Ali Zeaiter
    Ruth Plummer
    Cristiana Sessa
    Roger Von Moos
    Martin Forster
    Anastasios Stathis
    Investigational New Drugs, 2022, 40 : 91 - 98
  • [27] Combination Chemotherapy of Vinorelbine and Cisplatin: A Phase I Pharmacokinetic Study in Patients with Metastatic Solid Tumors
    Delord, Jean-Pierre
    Puozzo, Christian
    Lefresne, Florence
    Bugat, Roland
    ANTICANCER RESEARCH, 2009, 29 (02) : 553 - 560
  • [28] Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors
    Huie, M
    Carducci, M
    Liu, G
    Wilding, GG
    Marnocha, R
    Izquierda, M
    Thomas, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 613 - 617
  • [29] A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
    Ghalib, Mohammad H.
    Pulla, Mariano Provencio
    Luken, Maria J. De Miguel
    de Juan, Virginia Calvo
    Chaudhary, Imran
    Hammami, M. Bakri
    Vikash, Sindhu
    Maitra, Radhashree
    Martinez, Sara
    Kahatt, Carmen
    Extremera, Sonia
    Fudio, Salvador
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 481 - 491
  • [30] Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
    Hubbard, Joleen
    Erlichman, Charles
    Toft, David O.
    Qin, Rui
    Stensgard, Bridget A.
    Felten, Sara
    Ten Eyck, Cynthia
    Batzel, Gretchen
    Ivy, S. Percy
    Haluska, Paul
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 473 - 480
12345